CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Recommendation based on results from CheckMate -901, the first Phase 3 trial with an immunotherapy-chemotherapy combination to demonstrate a survival benefit versus standard-of-care chemotherapy...

Related Keywords

United States ,Japan ,Taiwan ,South Korea ,China ,Bristol Myers Squibb ,Dana Walker ,European Medicines Agency ,Company Opdivo ,Twitter ,Instagram ,Global Program ,Youtube ,Exchange Commission ,European Union ,European Commission ,Committee For Medicinal Products Human Use ,Ono Pharmaceutical Co ,Linkedin ,Drug Administration ,European Society Of Medical Oncology ,Facebook ,Medicinal Products ,Human Use ,Global Program Lead ,Genitourinary Cancers ,Bristol Myers ,European Society ,Medical Oncology ,Blinded Independent Central Review ,Hazard Ratio ,Confidence Interval ,Important Safety Information ,Myers Squibb ,Better Future ,Fatal Immune Mediated Adverse ,Full Prescribing Information ,Allogeneic Hematopoietic Stem Cell ,Multiple Myeloma ,Thalidomide Analogue ,Prescribing Information ,Ono Pharmaceutical ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Markets ,